English
简体中文
Total: £ 56.28
Published Date: 2025-07-17 | Pages: 84 | Tables: 82 | Pharma & Healthcare
The global market for Progressive Pulmonary Fibrosis (PPF) Treatment was valued at US$ 3756 million in the year 2024 and is projected to reach a revised size of US$ 6153 million by 2031, growing at a CAGR of 7.3% during the forecast period.
Progressive Pulmonary Fibrosis (PPF) treatment refers to medical strategies aimed at slowing the progression, alleviating symptoms, and improving the quality of life in patients with progressive fibrotic interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). These treatments include antifibrotic agents (e.g., nintedanib, pirfenidone), corticosteroids, immunosuppressants, oxygen therapy, pulmonary rehabilitation, and, in advanced cases, lung transplantation. PPF treatment is tailored based on disease behavior, imaging findings, and lung function decline, with the goal of reducing lung scarring and preserving respiratory capacity.
North American market for Progressive Pulmonary Fibrosis (PPF) Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Progressive Pulmonary Fibrosis (PPF) Treatment is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Progressive Pulmonary Fibrosis (PPF) Treatment in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Progressive Pulmonary Fibrosis (PPF) Treatment include Pliant Therapeutics, Bristol Myers Squibb, Veracyte, Bridge Biotherapeutics, Vicore Pharma, Roche, FibroGen, Novartis, United Therapeutics, Gilead Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Progressive Pulmonary Fibrosis (PPF) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Progressive Pulmonary Fibrosis (PPF) Treatment.
The Progressive Pulmonary Fibrosis (PPF) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Progressive Pulmonary Fibrosis (PPF) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Progressive Pulmonary Fibrosis (PPF) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pliant Therapeutics
Bristol Myers Squibb
Veracyte
Bridge Biotherapeutics
Vicore Pharma
Roche
FibroGen
Novartis
United Therapeutics
Gilead Sciences
Galecto Biotech
Avalyn Pharma
Segment by Type
Nintedanib
Pirfenidone
Corticosteroids
Immunosuppressants
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Progressive Pulmonary Fibrosis (PPF) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Nintedanib
1.2.3 Pirfenidone
1.2.4 Corticosteroids
1.2.5 Immunosuppressants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Perspective (2020-2031)
2.2 Global Progressive Pulmonary Fibrosis (PPF) Treatment Growth Trends by Region
2.2.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Progressive Pulmonary Fibrosis (PPF) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Progressive Pulmonary Fibrosis (PPF) Treatment Market Dynamics
2.3.1 Progressive Pulmonary Fibrosis (PPF) Treatment Industry Trends
2.3.2 Progressive Pulmonary Fibrosis (PPF) Treatment Market Drivers
2.3.3 Progressive Pulmonary Fibrosis (PPF) Treatment Market Challenges
2.3.4 Progressive Pulmonary Fibrosis (PPF) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Progressive Pulmonary Fibrosis (PPF) Treatment Players by Revenue
3.1.1 Global Top Progressive Pulmonary Fibrosis (PPF) Treatment Players by Revenue (2020-2025)
3.1.2 Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Top Progressive Pulmonary Fibrosis (PPF) Treatment Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Progressive Pulmonary Fibrosis (PPF) Treatment Revenue
3.4 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Concentration Ratio
3.4.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Progressive Pulmonary Fibrosis (PPF) Treatment Revenue in 2024
3.5 Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment Head office and Area Served
3.6 Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment, Product and Application
3.7 Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Progressive Pulmonary Fibrosis (PPF) Treatment Breakdown Data by Type
4.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Type (2026-2031)
5 Progressive Pulmonary Fibrosis (PPF) Treatment Breakdown Data by Application
5.1 Global Progressive Pulmonary Fibrosis (PPF) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (2020-2031)
6.2 North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025)
6.4 North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (2020-2031)
7.2 Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025)
7.4 Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (2020-2031)
9.2 Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025)
9.4 Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pliant Therapeutics
11.1.1 Pliant Therapeutics Company Details
11.1.2 Pliant Therapeutics Business Overview
11.1.3 Pliant Therapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.1.4 Pliant Therapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.1.5 Pliant Therapeutics Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.2.4 Bristol Myers Squibb Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Veracyte
11.3.1 Veracyte Company Details
11.3.2 Veracyte Business Overview
11.3.3 Veracyte Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.3.4 Veracyte Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.3.5 Veracyte Recent Development
11.4 Bridge Biotherapeutics
11.4.1 Bridge Biotherapeutics Company Details
11.4.2 Bridge Biotherapeutics Business Overview
11.4.3 Bridge Biotherapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.4.4 Bridge Biotherapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.4.5 Bridge Biotherapeutics Recent Development
11.5 Vicore Pharma
11.5.1 Vicore Pharma Company Details
11.5.2 Vicore Pharma Business Overview
11.5.3 Vicore Pharma Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.5.4 Vicore Pharma Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.5.5 Vicore Pharma Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.6.4 Roche Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.6.5 Roche Recent Development
11.7 FibroGen
11.7.1 FibroGen Company Details
11.7.2 FibroGen Business Overview
11.7.3 FibroGen Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.7.4 FibroGen Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.7.5 FibroGen Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.8.4 Novartis Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.8.5 Novartis Recent Development
11.9 United Therapeutics
11.9.1 United Therapeutics Company Details
11.9.2 United Therapeutics Business Overview
11.9.3 United Therapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.9.4 United Therapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.9.5 United Therapeutics Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Details
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.10.4 Gilead Sciences Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.10.5 Gilead Sciences Recent Development
11.11 Galecto Biotech
11.11.1 Galecto Biotech Company Details
11.11.2 Galecto Biotech Business Overview
11.11.3 Galecto Biotech Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.11.4 Galecto Biotech Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.11.5 Galecto Biotech Recent Development
11.12 Avalyn Pharma
11.12.1 Avalyn Pharma Company Details
11.12.2 Avalyn Pharma Business Overview
11.12.3 Avalyn Pharma Progressive Pulmonary Fibrosis (PPF) Treatment Introduction
11.12.4 Avalyn Pharma Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
11.12.5 Avalyn Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Nintedanib
Table 3. Key Players of Pirfenidone
Table 4. Key Players of Corticosteroids
Table 5. Key Players of Immunosuppressants
Table 6. Key Players of Others
Table 7. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Region (2020-2025)
Table 11. Global Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Region (2026-2031)
Table 13. Progressive Pulmonary Fibrosis (PPF) Treatment Market Trends
Table 14. Progressive Pulmonary Fibrosis (PPF) Treatment Market Drivers
Table 15. Progressive Pulmonary Fibrosis (PPF) Treatment Market Challenges
Table 16. Progressive Pulmonary Fibrosis (PPF) Treatment Market Restraints
Table 17. Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Players (2020-2025)
Table 19. Global Top Progressive Pulmonary Fibrosis (PPF) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment as of 2024)
Table 20. Ranking of Global Top Progressive Pulmonary Fibrosis (PPF) Treatment Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Progressive Pulmonary Fibrosis (PPF) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment, Headquarters and Area Served
Table 23. Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment, Product and Application
Table 24. Global Key Players of Progressive Pulmonary Fibrosis (PPF) Treatment, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue Market Share by Type (2020-2025)
Table 28. Global Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue Market Share by Type (2026-2031)
Table 30. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue Market Share by Application (2020-2025)
Table 32. Global Progressive Pulmonary Fibrosis (PPF) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Progressive Pulmonary Fibrosis (PPF) Treatment Revenue Market Share by Application (2026-2031)
Table 34. North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 49. Pliant Therapeutics Company Details
Table 50. Pliant Therapeutics Business Overview
Table 51. Pliant Therapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 52. Pliant Therapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 53. Pliant Therapeutics Recent Development
Table 54. Bristol Myers Squibb Company Details
Table 55. Bristol Myers Squibb Business Overview
Table 56. Bristol Myers Squibb Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 57. Bristol Myers Squibb Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 58. Bristol Myers Squibb Recent Development
Table 59. Veracyte Company Details
Table 60. Veracyte Business Overview
Table 61. Veracyte Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 62. Veracyte Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 63. Veracyte Recent Development
Table 64. Bridge Biotherapeutics Company Details
Table 65. Bridge Biotherapeutics Business Overview
Table 66. Bridge Biotherapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 67. Bridge Biotherapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 68. Bridge Biotherapeutics Recent Development
Table 69. Vicore Pharma Company Details
Table 70. Vicore Pharma Business Overview
Table 71. Vicore Pharma Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 72. Vicore Pharma Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 73. Vicore Pharma Recent Development
Table 74. Roche Company Details
Table 75. Roche Business Overview
Table 76. Roche Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 77. Roche Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 78. Roche Recent Development
Table 79. FibroGen Company Details
Table 80. FibroGen Business Overview
Table 81. FibroGen Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 82. FibroGen Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 83. FibroGen Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 87. Novartis Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 88. Novartis Recent Development
Table 89. United Therapeutics Company Details
Table 90. United Therapeutics Business Overview
Table 91. United Therapeutics Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 92. United Therapeutics Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 93. United Therapeutics Recent Development
Table 94. Gilead Sciences Company Details
Table 95. Gilead Sciences Business Overview
Table 96. Gilead Sciences Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 97. Gilead Sciences Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 98. Gilead Sciences Recent Development
Table 99. Galecto Biotech Company Details
Table 100. Galecto Biotech Business Overview
Table 101. Galecto Biotech Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 102. Galecto Biotech Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 103. Galecto Biotech Recent Development
Table 104. Avalyn Pharma Company Details
Table 105. Avalyn Pharma Business Overview
Table 106. Avalyn Pharma Progressive Pulmonary Fibrosis (PPF) Treatment Product
Table 107. Avalyn Pharma Revenue in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025) & (US$ Million)
Table 108. Avalyn Pharma Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
Table 112. Authors List of This Report
List of Figures
Figure 1. Progressive Pulmonary Fibrosis (PPF) Treatment Picture
Figure 2. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Nintedanib Features
Figure 5. Pirfenidone Features
Figure 6. Corticosteroids Features
Figure 7. Immunosuppressants Features
Figure 8. Others Features
Figure 9. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Retail Pharmacy Case Studies
Figure 13. Others Case Studies
Figure 14. Progressive Pulmonary Fibrosis (PPF) Treatment Report Years Considered
Figure 15. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Region: 2024 VS 2031
Figure 18. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Players in 2024
Figure 19. Global Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Progressive Pulmonary Fibrosis (PPF) Treatment Revenue in 2024
Figure 21. North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Country (2020-2031)
Figure 23. United States Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Country (2020-2031)
Figure 27. Germany Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Ireland Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Region (2020-2031)
Figure 35. China Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia & New Zealand Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Country (2020-2031)
Figure 43. Mexico Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Progressive Pulmonary Fibrosis (PPF) Treatment Market Share by Country (2020-2031)
Figure 47. Israel Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Progressive Pulmonary Fibrosis (PPF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Pliant Therapeutics Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 51. Bristol Myers Squibb Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 52. Veracyte Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 53. Bridge Biotherapeutics Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 54. Vicore Pharma Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 55. Roche Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 56. FibroGen Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 58. United Therapeutics Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 59. Gilead Sciences Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 60. Galecto Biotech Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 61. Avalyn Pharma Revenue Growth Rate in Progressive Pulmonary Fibrosis (PPF) Treatment Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
